Lunai Bioworks Inc. (RENB) NASDAQ
1.42
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.42
+0(+0.00%)
Currency In USD
| Previous Close | 1.42 |
| Open | 1.19 |
| Day High | 1.42 |
| Day Low | 1.19 |
| 52-Week High | 21 |
| 52-Week Low | 1.12 |
| Volume | 808,780 |
| Average Volume | 218,513 |
| Market Cap | 32.92M |
| PE | -0.13 |
| EPS | -10.8 |
| Moving Average 50 Days | 1.96 |
| Moving Average 200 Days | 4.41 |
| Change | 0 |
Data not available
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
GlobeNewswire Inc.
Jun 03, 2025 1:15 PM GMT
Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, tod
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
GlobeNewswire Inc.
May 22, 2025 7:12 PM GMT
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedit
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
GlobeNewswire Inc.
May 22, 2025 3:05 PM GMT
LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedit